Literature DB >> 31750023

Functional gastrointestinal disorders negatively affect health-related quality of life in MS.

Ruth Ann Marrie1, Stella Leung1, Tuula Tyry1, Gary R Cutter1, Robert Fox1, Amber Salter1.   

Abstract

OBJECTIVE: To determine the prevalence of functional gastrointestinal disorders, the demographic and clinical characteristics associated with the presence of functional gastrointestinal disorders, and the effects of these disorders with health-related quality of life (HRQOL) in a large, diverse population of persons with MS.
METHODS: In 2014, we surveyed participants in the North American Research Committee on Multiple Sclerosis registry regarding functional gastrointestinal disorders using the Rome III questionnaire. Participants also reported their sociodemographic characteristics, disability status using Patient Determined Disease Steps, the presence of comorbid depression and anxiety, health behaviors, and HRQOL using the RAND-12. We determined the prevalence of each gastrointestinal disorder using the Rome III criteria. Using multivariable logistic regression models, we assessed the factors associated with the presence of each bowel disorder. Using linear regression, we evaluated the association between functional gastrointestinal disorders and HRQOL.
RESULTS: Of 6,312 eligible respondents, 76.5% were female, with a mean (SD) age of 58.3 (10.2) years. Forty-two percent of respondents (n = 2,647) had a functional gastrointestinal disorder, most often irritable bowel syndrome (IBS), which affected 28.2% of participants. The prevalence of all functional gastrointestinal disorders increased with greater disability, and the prevalence of IBS increased with longer disease duration. After adjusting for sociodemographic and clinical characteristics, functional gastrointestinal disorders were associated with lower physical and mental HRQOL (both p < 0.0001).
CONCLUSIONS: Functional gastrointestinal disorders are common in MS and are associated with reduced HRQOL.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31750023      PMCID: PMC6814419          DOI: 10.1212/CPJ.0000000000000668

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  33 in total

1.  Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population.

Authors:  M W Nortvedt; T Riise; K M Myhr; H I Nyland
Journal:  Med Care       Date:  2000-10       Impact factor: 2.983

2.  Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Authors:  Guoqiao Wang; Ruth Ann Marrie; Robert J Fox; Tuula Tyry; Stacey S Cofield; Gary R Cutter; Amber Salter
Journal:  Mult Scler Relat Disord       Date:  2017-12-14       Impact factor: 4.339

3.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.

Authors:  K Bush; D R Kivlahan; M B McDonell; S D Fihn; K A Bradley
Journal:  Arch Intern Med       Date:  1998-09-14

4.  Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.

Authors:  Pierre Paré; James Gray; Sy Lam; Robert Balshaw; Shideh Khorasheh; Martin Barbeau; Suzanne Kelly; Christopher R McBurney
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

5.  Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis.

Authors:  M W Nortvedt; T Riise; J Frugård; J Mohn; A Bakke; A B Skår; H Nyland; S B Glad; K M Myhr
Journal:  Mult Scler       Date:  2007-01       Impact factor: 6.312

Review 6.  Cytokines and irritable bowel syndrome: where do we stand?

Authors:  Mohammad Bashashati; Nima Rezaei; Christopher N Andrews; Chun-Qiu Chen; Nasser Ebrahimi Daryani; Keith A Sharkey; Martin A Storr
Journal:  Cytokine       Date:  2011-12-16       Impact factor: 3.861

7.  Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction.

Authors:  Marianna Vitkova; Jaroslav Rosenberger; Martina Krokavcova; Jarmila Szilasiova; Zuzana Gdovinova; Johan W Groothoff; Jitse P van Dijk
Journal:  Disabil Rehabil       Date:  2013-08-20       Impact factor: 3.033

8.  Validity of performance scales for disability assessment in multiple sclerosis.

Authors:  R A Marrie; M Goldman
Journal:  Mult Scler       Date:  2007-07-10       Impact factor: 6.312

9.  Comorbidity, socioeconomic status and multiple sclerosis.

Authors:  Ra Marrie; R Horwitz; G Cutter; T Tyry; D Campagnolo; T Vollmer
Journal:  Mult Scler       Date:  2008-09       Impact factor: 6.312

10.  Differences in the burden of psychiatric comorbidity in MS vs the general population.

Authors:  Ruth Ann Marrie; John D Fisk; Helen Tremlett; Christina Wolfson; Sharon Warren; Aruni Tennakoon; Stella Leung; Scott B Patten
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

View more
  2 in total

1.  Neurogenic Bowel Dysfunction Over the Course of Multiple Sclerosis: A Review.

Authors:  Elsie E Gulick
Journal:  Int J MS Care       Date:  2022-06-20

Review 2.  Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.

Authors:  Lynsey Lakin; Bryan E Davis; Cherie C Binns; Keisha M Currie; Mary R Rensel
Journal:  Neurol Ther       Date:  2021-04-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.